If you are expecting an erudite and pithy exposition of my considerable knowledge on COVID (I am a veteran of the ‘Vid) and my extensive wisdom as an Internet immunologist, public health official, medical raconteur, and epidemiologist — you will be disappointed. I am sorry.

Today, I speak only of one company – Moderna.

The Pandemic has been very good to Moderna — this is not a slur or a casting of aspersions of any form whatever. It is simply a reflection of Moderna’s stock price. Continue reading →